Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
N Engl J Med. Author manuscript; available in PMC 2011 June 30.
Published in final edited form as:
PMCID: PMC3069846

Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease



Failure to generate phagocyte-derived superoxide and related reactive oxygen intermediates (ROIs) is the major defect in chronic granulomatous disease, causing recurrent infections and granulomatous complications. Chronic granulomatous disease is caused by missense, nonsense, frameshift, splice, or deletion mutations in the genes for p22phox, p40phox, p47phox, p67phox (autosomal chronic granulomatous disease), or gp91phox (X-linked chronic granulomatous disease), which result in variable production of neutrophil-derived ROIs. We hypothesized that residual ROI production might be linked to survival in patients with chronic granulomatous disease.


We assessed the risks of illness and death among 287 patients with chronic granulomatous disease from 244 kindreds. Residual ROI production was measured with the use of superoxide-dependent ferricytochrome c reduction and flow cytometry with dihydrorhodamine oxidation assays. Expression of NADPH oxidase component protein was detected by means of immunoblotting, and the affected genes were sequenced to identify causal mutations.


Survival of patients with chronic granulomatous disease was strongly associated with residual ROI production as a continuous variable, independently of the specific gene affected. Patients with mutations in p47phox and most missense mutations in gp91phox (with the exception of missense mutations in the nucleotide-binding and heme-binding domains) had more residual ROI production than patients with nonsense, frameshift, splice, or deletion mutations in gp91phox. After adolescence, mortality curves diverged according to the extent of residual ROI production.


Patients with chronic granulomatous disease and modest residual production of ROI have significantly less severe illness and a greater likelihood of long-term survival than patients with little residual ROI production. The production of residual ROI is predicted by the specific NADPH oxidase mutation, regardless of the specific gene affected, and it is a predictor of survival in patients with chronic granulomatous disease. (Funded by the National Institutes of Health.)

Chronic Granulomatous Disease, first described in the 1950s,1 is a rare genetic disease (approximately 1 case in 200,000 people) without ethnic preference. The risk of death among persons with chronic granulomatous disease is 1 to 5% per year, and the extent of risk has been thought to depend on whether inheritance is an autosomal recessive trait or an X-linked trait.2 Chronic granulomatous disease is caused by defects in any one of five subunits of phagocyte-derived NADPH oxidase, including gp91phox (CYBB [cytochrome b-245, beta polypeptide], in approximately 65% of patients), p22phox (CYBA [cytochrome b-245, alpha polypeptide], <5%), p47phox (NCF1 [neutrophil cytosolic factor 1], approximately 30%), p67phox (NCF2 [neutrophil cytosolic factor 2], <5%), and p40phox (NCF4 [neutrophil cytosolic factor 4], one case identified)3; in rare cases there is an association with glucose-6-phosphate dehydrogenase.4 In patients with chronic granulomatous disease, the production of superoxide anion and other reactive oxygen intermediates (ROIs) by neutrophils, monocytes, macrophages, and eosinophils is impaired, leading to recurrent infections, granulomatous complications, and premature death.

Although the functioning of phagocyte NADPH oxidase is impaired in all patients with chronic granulomatous disease, there is variability among patients in the phagocytic production of residual ROIs (0.1 to 27.0% of the normal range). Analysis of this residual ROI production allows for the separation of patients with chronic granulomatous disease into subgroups with different mortality rates.


Isolation of Neutrophils and Mononuclear Cells

We obtained heparinized blood specimens from both healthy subjects and patients with chronic granulomatous disease starting in 1993. Participants provided written informed consent in accordance with clinical protocols approved by the National Institutes of Health. Peripheral-blood polymorphonuclear neutrophils and mononuclear cells were harvested from diluted blood with the use of discontinuous gradient centrifugation.5

Activity of NADPH OXIDASE and Detection of Components

Production of neutrophil-derived ROI by patients with chronic granulomatous disease was measured with either a dihydrorhodamine oxidation assay (a myeloperoxidase-dependent6 measure of hydrogen peroxide production), or superoxide-dependent ferricytochrome c reduction stimulated by phorbol myristate acetate. ROI production was stable over time (for details, see section 1 in the Supplementary Appendix, available with the full text of this article at For the dihydrorhodamine assay, the duration of stimulation with phorbol myristate acetate (100 ng per milliliter) was 15 minutes; the duration of the ferricytochrome c–superoxide quantitation was extended to 60 minutes to increase sensitivity. NADPH oxidase protein subunits in neutrophils from patients with chronic granulomatous disease were detected by means of immunoblotting (Fig. 1 in the Supplementary Appendix).5

Gene-Sequence Analysis

Genomic DNA was isolated with the use of the Gentra Puregene kit (Qiagen) and was sequenced by means of standard techniques. (For details, see section 2 and Tables 1 and 2 in the Supplementary Appendix)

Statistical Analyses

For univariate and multivariate analyses based on ROI production, the amounts of superoxide and the mean fluorescence intensity of dihydrorhodamine were transformed to their common (base-10) logarithms. Factors associated with mortality were evaluated with the use of standard log-rank Kaplan–Meier methods and Cox proportional-hazards regression.7 Time-to-event calculations were based on the birth date and the date of final follow-up or death. The values for superoxide and dihydrorhodamine were dichotomized in Cox regression analyses; hazard ratios and associated 95% confidence intervals were reported. Assumptions underlying the Cox proportional-hazards regression models were routinely evaluated with the use of Schoenfeld's residuals.7 Standard t-tests, logistic regression, and clustering methods were also used.8,9 Statistical analyses were performed with the use of SAS, version 9.1 (SAS Institute); S-Plus, version 8.0 (TIBCO); and R, version 2.9.2 (R Development Core Team), software.


Characteristics of Study Participants

Demographic and survival data plus certain clinical variables previously correlated with survival (history of liver abscesses, rise in alkaline phosphatase, and decrease in platelet count8) were reviewed for 287 patients with chronic granulomatous disease from 244 kindreds. A combination of genotyping and immunoblotting showed that the group was composed of 195 patients (from 169 families) with X-linked disease (gp91phox deficiency, 67.9%), 71 patients (54 families) with p47phox deficiency (24.7%), 13 patients (13 families) with p67phox deficiency (4.5%), and 8 patients (8 families) with p22phox deficiency (2.8%). One female patient had gp91phox deficiency as a result of extreme X-chromosome inactivation.10 The autosomal recessive genotypes had a fairly equal distribution with regard to the sex of patients. At the time of the last assessment or death, the patients ranged in age from 1 to 64 years; 32 had died. Three patients died within 18 months of bone marrow transplantation, and 15 others who underwent bone marrow transplantation were included among the survivors. The censoring of data for these 18 patients at the time of transplantation did not alter the overall interpretation of the survival data.

Residual ROI Production and Survival

Dihydrorhodamine measures the oxidation of dihydrorhodamine 123 to rhodamine 123 in phorbol myristate acetate–stimulated polymorphonuclear neutrophils. In exploratory analyses, we investigated the relationship between the dihydrorhodamine mean fluorescence intensity and 60-minute superoxide production in 197 patients for whom we had data on both dihydrorhodamine and superoxide production (Fig. 1A). Correlation between log10 superoxide production and log10 dihydrorhodamine mean fluorescence intensity (r=0.67, P<0.001) confirmed the expected covariation between the two measures. The data were empirically separated into two distinct subpopulations on the basis of superoxide production (<2.3 vs. ≥2.3 nmol per 106 cells per hour) and dihydrorhodamine fluorescence (<225 vs. ≥225 arbitrary units [AU]). We then applied a “partitioning around medoids” clustering algorithm9 to assort the data into two clusters. On the basis of ROI production alone, there was 91% agreement between the two approaches. Ten of 11 patients (Fig. 1A) who died fell into the lower left quadrant, reflecting the lowest ROI values. Dichotomized ROI values separated the survival groups (P=0.002) (Fig. 1B). Cox regression analysis, performed with the use of the empirical discriminators listed above, showed that these variables, considered together, have a strong predictive association with survival (P=0.008) (section 3 and Table 3 in the Supplementary Appendix).

Figure 1
Production of Reactive Oxygen Intermediates and Survival in Chronic Granulomatous Disease

Using superoxide production as the sole predictor, we fit Cox regression models to survival data from 227 patients with chronic granulomatous disease in exploratory analyses. Patients were first ranked into four discrete quartiles according to neutrophil superoxide production (Fig. 1C), without consideration of their disease phenotype. Survival increased with higher superoxide production (Fig. 1C, inset, and Fig. 2A). Taking the quartile with the lowest superoxide production (quartile 1) as the reference group, we observed graded increases in the hazard ratios corresponding to increasing superoxide production in quartiles 2, 3, and 4. When log10 superoxide production was considered as a continuous covariate, the strength of this relationship increased (P<0.001; likelihood ratio chi-square=11.08, 1 degree of freedom). These findings showed that higher residual superoxide production was a predictor of longer survival.

Figure 2
Defining Characteristics and Subtype Composition of the Study Quartiles for Patients with Chronic Granulomatous Disease

The significant morbidity associated with chronic granulomatous disease is related to granuloma formation and obstruction of viscus organs, especially the gastrointestinal and genitourinary tracts. Fifty-five patients had gastrointestinal obstruction, but gastrointestinal complications were not associated with the level of ROI production (Fig. 2 in the Supplementary Appendix). A history of liver abscess, a declining platelet slope (a loss of more than 9000 platelets per cubic millimeter per year), and increases in the level of alkaline phosphatase (>0.25 U per liter per year) have been identified as risk factors independently associated with mortality.8 Univariate analysis of dihydrorhodamine fluorescence in 139 patients confirmed that lower values were significantly associated with mortality (<225 AU vs. ≥225 AU) (P = 0.02) (Table 1). In bivariate analyses that included dihydrorhodamine values, both a history of liver abscess and increases in alkaline phosphatase as covariates were significantly associated with mortality, independently of dihydrorhodamine values of less than 225 AU. In contrast, the association of a declining platelet slope with a poor outcome was not significant after adjustment for dihydrorhodamine values of less than 225 AU. Notably, patients who had dihydrorhodamine fluorescence values below this level were more likely to have a declining platelet slope (odds ratio, 2.50; 95% confidence interval, 1.09 to 5.73; P = 0.03). This suggests that a declining platelet slope, which is a marker of noncirrhotic portal hypertension, is related to ROI production, whereas the contributions of a history of liver abscess and alkaline phosphatase elevations to mortality were independent.

Table 1
Results of Univariate and Bivariate Cox Regression Models Showing the Association between Dihydrorhodamine Fluorescence Values and Mortality among Patients with Chronic Granulomatous Disease


Among the 273 patients who underwent complete genotyping, 154 distinct mutations were found (Fig. 3A, and Tables 4 through 7 in the Supplementary Appendix) distributed along the entire length of the gp91phox gene, CYBB; 55 mutations were novel,11 including 45 X-linked missense and nonsense mutations. Fewer nonsense than missense mutations were noted, but many nonsense mutations occurred in multiple kindreds. More than 50% of the nonsense, missense, or splice mutations in CYBB were C→T (or its complementary G→A) conversions (Fig. 4 in the Supplementary Appendix), suggesting that many mutations arose from deamination of 5-methylcytosine to thymine, as reported for other diseases.12 For nonsense mutations, 80% were C→T (or G→A) conversions at CpG dinucleotides. Mutational hotspots were identified at CYBB c.676C→T (p.Arg226X), c.217C→T (p.Arg73X), c.388C→T (p.Arg130X), and c.469C→T (p.Arg157X) (Fig. 3 in the Supplementary Appendix). Two male patients with 388C→T (R130X) had somatic mosaicism, with levels of circulating normal cells of less than 10%. Five patients with CYBB mutations had nonsense hotspot mutations that were apparently de novo, since their mothers had only one peak in the dihydrorhodamine assay and had normal CYBB genotypes. Two brothers had CYBB promoter mutations that preserved normal NADPH oxidase activity in eosinophils but abrogated activity in neutrophils (Patients gp91-1a and gp91-1b) (Table 4 in the Supplementary Appendix), confirming a previous report.13

Frameshift mutations (deletions or insertions) were also randomly distributed throughout CYBB. Splice mutations occurred mostly at canonical intron splice-donor (GT) or acceptor sites (AG), resulting in deletions of exons from messenger RNA (Fig. 3A, and Fig. 3 in the Supplementary Appendix). However, several splice mutations that have been reported previously (in Patients gp91-17,14 gp91-33,15 gp91-142a,14 and gp91-147a14) and one mutation that has not been reported (in Patient gp91-125a) (Table 4 in the Supplementary Appendix) created new splice sites that resulted in either insertions or deletions within the exons, out-of-frame triplet codons, or premature termination of gp91phox. Eight kindreds had no detectable exons of CYBB, and in six patients, the large deletion extended into the adjacent XK, resulting in the McLeod syndrome.16

Seventy-one patients (54 kindreds) had p47phox deficiency (Table 5 in the Supplementary Appendix). Complementary DNA sequencing in 61 patients revealed that 59 were homozygous and 2 were heterozygous for the common GT deletion at the start of exon 2 of NCF1.17,18 The second mutation in the 2 heterozygous patients was not identified by the described sequencing approach.

Patients with p22phox deficiency or p67phox deficiency had missense, nonsense, splice, or deletion mutations in CYBA and NCF2, respectively, and most were homozygous (Tables 6 and 7 in the Supplementary Appendix). Previously unreported mutations in p22phox were noted in three patients (p22-4, p22-5, and p22-7) (Table 6 in the Supplementary Appendix). Similarly, previously unreported mutations in p67phox occurred in six patients (p67-1, p67-2, p67-4, p67-6, p67-8, and p67-9) (Table 7 in the Supplementary Appendix).

Genotype, Phenotype, and Residual ROI

Neutrophil protein expression and residual ROI production were determined for each mutation (Tables 4 through 7 in the Supplementary Appendix). The gp91phox protein was detected in polymorphonuclear neutrophils from less than half the patients with X-linked disease who had CYBB missense mutations (Fig. 3B), suggesting that most CYBB missense mutations impair protein stability or translational efficiency. The neutrophils from all patients with p47phox deficiency lacked detectable levels of p47phox protein. Most patients with p22phox and p67phox deficiency had no detectable protein production. One patient with p67phox deficiency (p67-9) (Table 7 in the Supplementary Appendix) had levels of p67phox production that were close to normal.

Figure 3 (facing page)
Distribution of Mutations in gp91phox, p22phox, p47phox, and p67phox and the Consequences of Mutations in gp91phox

Because gp91phox has several discrete functional domains, we explored the missense mutations in more detail. Neutrophils from patients with missense mutations affecting amino acids 1 to 309 (with the exception of heme-binding His222) had a mean (±SE) level of superoxide production that was 10 times as high as that in neutrophils from patients with missense mutations affecting amino acids 310 to 570, a region that includes the binding domains of FAD (flavin adenine dinucleotide) and NADPH (14.42±4.67 nmol per 106 cells per hour vs. 1.53±0.24 nmol per 106 cells per hour, P<0.001 (Table 2 and Fig. 3B). Although previous schemes for denoting gp91phox mutations have relied on protein expression, we found that missense mutations in the predicted nucleotide-binding domains (amino acids 310 to 570) often had little effect on protein expression but completely abrogated enzymatic function.19-21 Therefore, gp91phox protein expression is not a reliable indicator of residual ROI production. In general, patients with nonsense, frameshift, splice, or deletion mutations in gp91phox had neither superoxide production nor protein expression (Table 2 and Fig. 3B, and Table 4 in the Supplementary Appendix).

Table 2
Production of Reactive Oxygen Intermediates According to Mutation Associated with Chronic Granulomatous Disease

Residual ROI production in neutrophils from patients with p47phox deficiency was greater than that in patients with nonsense, frameshift, splice, or deletion mutations in gp91phox (P<0.001). Overlaying patient genotype on the scatter plot in Figure 1A revealed that patients with nonsense, frameshift, splice, or deletion mutations in gp91phox generally had the lowest ROI production (Fig. 1D). Patients with p47phox deficiency and many patients with gp91phox missense mutations were located above and to the right of the lowest ROI producers in Figure 1D, reflecting higher ROI production (Table 2, and Tables 4 and 5 in the Supplementary Appendix). In the quartile analysis (Fig. 1C and and2B),2B), 44 patients in quartile 1 had nonsense, frameshift, splice, or deletion mutations in gp91phox, as compared with 5 patients in quartile 4. This was accompanied by reciprocal increases in the number of patients with p47phox deficiency (1 in quartile 1 vs. 32 in quartile 4) and missense mutations in gp91phox (7 in quartile 1 vs. 17 in quartile 4), especially missense mutations in gp91phox affecting amino acids 1 to 309 (0 in quartile 1 vs. 14 in quartile 4). The range of ROI production in patients with p22phox deficiency or p67phox deficiency varied widely, with the highest production seen in patients with missense mutations; the patients in quartile 4 with these deficiencies had missense mutations (Fig. 2B).

Genotype, Type of Mutation, and Survival

The rate of survival was lower among patients with X-linked chronic granulomatous disease than among those with autosomal recessive disease (P = 0.008) (Fig. 5A in the Supplementary Appendix), confirming previous reports.3,22 Survival among patients with gp91phox missense mutations was similar to that among patients with p47phox deficiency. Both groups, however, had significantly lower rates of survival than the general U.S. population23 (P<0.001 (Fig. 5B in the Supplementary Appendix). In contrast, patients with nonsense, frameshift, deletion, or splice mutations in gp91phox had shorter survival than those with mutations in p47phox (P = 0.008).


Survival among patients with chronic granulomatous disease has improved since its first description in the 1950s. This change is attributed to better recognition of the disease and an understanding of its pathophysiology, development of more effective antimicrobial agents,24,25 interferon-γ prophylaxis,26 and bone marrow transplantation.27 Survival in our cohort of 287 patients from 244 families studied over the past 20 years at a single center shows that childhood death from chronic granulomatous disease is now uncommon, as previously described.2,22,28 Previously reported differences in morbidity and mortality between X-linked and autosomal chronic granulomatous disease2,22,29 were seen in our cohort but did not account for the substantial variation in survival rates among our patients. Our data indicate that residual ROI production is more predictive of survival than the specific NADPH-oxidase gene mutation. Even modest residual ROI production (1% of normal production) confers a significant survival benefit. This finding has important implications for the treatment of chronic granulomatous disease.

The longer survival of patients with chronic granulomatous disease has revealed the cumulative effects of frequent serious infections and of a spectrum of noninfectious inflammatory and autoimmune disorders.2,30,31 One important consequence of severe infections — of the lungs and liver, in particular — is a predisposition to subsequent infections.32,33 Furthermore, the exaggerated inflammatory responses of chronic granulomatous disease (e.g., dysregulated cytokine production34,35 and decreased apoptosis36) probably contribute to increased scar formation, wound dehiscence, stricture development, and other problems that complicate recovery.

Our data indicate that neutrophil production of residual ROI predicts the risk of death among patients with chronic granulomatous disease and that genetic analysis can, in many cases, predict ROI production. Missense and frameshift mutations in gp91phox were randomly distributed throughout the gene and were generally family-specific, whereas nonsense and spontaneous mutations were concentrated at discrete CpG dinucleotide hotspots, confirming similar findings in other diseases. Little residual ROI production was observed in patients with nonsense, frameshift, splice, or deletion mutations in gp91phox. Patients with p47phox deficiency had increased production of neutrophil ROI and increased survival, as compared with patients with nonfunctional gp91phox mutations. Unexpectedly, patients with missense mutations affecting gp91phox amino acids 1 to 309 (with the exception of heme-binding His222) had even higher residual ROI production than was observed in patients with p47phox deficiency. ROI production was not correlated with protein expression. Mutations in the FAD-binding and NADPH-binding domains of gp91phox may allow normal protein expression but little residual ROI production, indicating the critical role of these domains.19-21 Whereas protein detection provides important clues to the diagnosis of chronic granulomatous disease, quantitative ROI measurement, which correlates closely with gene sequence, is more useful in determining a patient's long-term risk. However, occasional variability in ROI production and clinical outcome in patients with the same mutation — as reported here (in Patients gp91-24a, gp91-25a, and gp91-26a or Patients gp91-98a, gp-99a, and gp-99b) and elsewhere37 — cannot be explained solely by the mutation, suggesting that epigenetic factors or other modifying genes may play an important role.38

Neutrophil ROI production is a measure that can be obtained at diagnosis, correlates with genotype, and is a strong predictor of overall survival in patients with chronic granulomatous disease. Early risk assessment based on ROI production provides additional guidance for the triage of patients for more aggressive therapies such as bone marrow transplantation, which has been shown in other hematologic disorders to be more effective when performed early in life.39,40 Our results do not suggest that the use of established standard-of-care prophylaxis and periodic clinical assessment can be ignored in the case of patients in whom neutrophils produce more residual ROI. However, our finding that even small amounts of neutrophil production of ROI confer a significant survival benefit suggests that therapies promoting even small increases in ROI production may improve survival.

Supplementary Material



Supported by intramural grants from the National Institute of Allergy and Infectious Diseases (Z01-AI-000155, Z01-AI-000645, and Z01-AI-00646-06), a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (ZIA DK075008-04 LDB), and a contract from the National Cancer Institute (HH-SN261200800001E).


The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Disclosure forms provided by the authors are available with the full text of this article at


1. Berendes H, Bridges RA, Good RA. A fatal granulomatosus of childhood: the clinical study of a new syndrome. Minn Med. 1957;40:309–12. [PubMed]
2. Winkelstein JA, Marino MC, Johnston RB, Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155–69. [PubMed]
3. Matute JD, Arias AA, Wright NAM, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40phox and selective defects in neutrophil NADPH oxidase activity. Blood. 2009;114:3309–15. [PubMed]
4. Cooper MR, DeChatelet LR, McCall CE, Lavia MF, Spurr CL, Baehner RL. Complete deficiency of leukocyte glucose-6-phosphate dehydrogenase with defective bactericidal activity. J Clin Invest. 1972;51:769–78. [PMC free article] [PubMed]
5. Jirapongsananuruk O, Malech HL, Kuhns DB, et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. J Allergy Clin Immunol. 2003;111:374–9. [PubMed]
6. Mauch L, Lun A, O'Gorman MRG, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007;53:890–6. [PubMed]
7. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994.
8. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology. 2008;134:1917–26. [PMC free article] [PubMed]
9. Kaufman L, Rousseeuw PJ. Finding groups in data: an introduction to cluster analysis. New York: Wiley Interscience; 1990.
10. Anderson-Cohen M, Holland SM, Kuhns DB, et al. Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a nonfamilial, extremely skewed X chromosome inactivation. Clin Immunol. 2003;109:308–17. [PubMed]
11. Piirilä H, Väliaho J, Vihinen M. Immunodeficiency mutation databases (IDbases) Hum Mutat. 2006;27:1200–8. [PubMed]
12. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78:151–5. [PubMed]
13. Weening RS, De Boer M, Kuijpers TW, Neefjes VME, Hack WWM, Roos D. Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease. Clin Exp Immunol. 2000;122:410–7. [PubMed]
14. Heyworth PG, Curnutte JT, Rae J, et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update) Blood Cells Mol Dis. 2001;27:16–26. [PubMed]
15. Rae J, Newburger PE, Dinauer MC, et al. X-linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet. 1998;62:1320–31. [PubMed]
16. Frey D, Mächler M, Seger R, Schmid W, Orkin SH. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood. 1988;71:252–5. [PubMed]
17. Volpp BD, Lin Y. In vitro molecular reconstitution of the respiratory burst in B lymphoblasts from p47-phox-deficient chronic granulomatous disease. J Clin Invest. 1993;91:201–7. [PMC free article] [PubMed]
18. Cross AR, Curnutte JT, Heyworth PG. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease. Blood Cells Mol Dis. 1996;22:268–70. [PubMed]
19. Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL. Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem. 1990;265:8745–50. [PubMed]
20. Yoshida LS, Saruta F, Yoshikawa K, Tatsuzawa O, Tsunawaki S. Mutation at histidine 338 of gp91phox depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. J Biol Chem. 1998;273:27879–86. [PubMed]
21. Han CH, Nisimoto Y, Lee SH, Kim ET, Lambeth JD. Characterization of the flavoprotein domain of gp91phox which has NADPH diaphorase activity. J Biochem. 2001;129:513–20. [PubMed]
22. van den Berg JM, van Koppen E, Åhlin A, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234. [PMC free article] [PubMed]
23. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56(10):1–120. [PubMed]
24. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990;162:723–6. [PubMed]
25. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348:2416–22. [PubMed]
26. The International Chronic Granulomatous Disease Cooperative Study Group A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324:509–16. [PubMed]
27. Kang EM, Malech HL. Advances in treatment for chronic granulomatous disease. Immunol Res. 2009;43:77–84. [PubMed]
28. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-γ therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39:692–9. [PubMed]
29. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114:462–8. [PubMed]
30. Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol. 2000;120:351–5. [PubMed]
31. De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122:1097–103. [PMC free article] [PubMed]
32. Guide SV, Stock F, Gill VJ, et al. Reinfection, rather than persistent infection, in patients with chronic granulomatous disease. J Infect Dis. 2003;187:845–53. [PubMed]
33. Carnide EG, Jacob CA, Castro AM, Pastorino AC. Clinical and laboratory aspects of chronic granulomatous disease in description of eighteen patients. Pediatr Allergy Immunol. 2005;16:5–9. [PubMed]
34. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol. 2005;174:411–7. [PubMed]
35. van de Veerdonk FL, Smeekens SP, Joosten LA, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107:3030–3. [PubMed]
36. Kasahara Y, Iwai K, Yachie A, et al. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood. 1997;89:1748–53. [PubMed]
37. Schapiro BL, Newburger PE, Klempner MS, Dinauer MC. Chronic granulomatous disease presenting in a 69-year-old man. N Engl J Med. 1991;325:1786–90. [PubMed]
38. Foster CBF, Lehrnbecher T, Mol FM, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest. 1998;102:2146–55. [PMC free article] [PubMed]
39. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329:840–4. [PubMed]
40. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104:1201–3. [PubMed]